Validity of the EQ-5D-5L and EQ-5D-3L in patients with Crohn's disease.


Journal

Quality of life research : an international journal of quality of life aspects of treatment, care and rehabilitation
ISSN: 1573-2649
Titre abrégé: Qual Life Res
Pays: Netherlands
ID NLM: 9210257

Informations de publication

Date de publication:
Jan 2019
Historique:
accepted: 11 09 2018
pubmed: 19 9 2018
medline: 21 3 2019
entrez: 19 9 2018
Statut: ppublish

Résumé

The EuroQol five-dimension questionnaire (EQ-5D) is the most commonly used instrument to obtain utility values for cost-effectiveness analyses of treatments for Crohn's disease (CD). We aimed to compare the measurement properties of the two adult versions of EQ-5D (EQ-5D-3L and EQ-5D-5L) in patients with CD. Between 2016 and 2017, a multicentre cross-sectional survey was carried out. Consecutive outpatients with CD completed the 3L, 5L and EQ visual analogue scale (VAS). Disease severity was graded by the Crohn's Disease Activity Index (CDAI) and Perianal Disease Activity Index (PDAI). The 3L and 5L were compared in terms of feasibility, agreement, ceiling effect, redistribution properties, discriminatory power, convergent and known-groups validity. Two-hundred and six patients (54.9% male, mean age 35 ± 11 years) participated in the survey. For 3L, 25 unique health states were observed versus 59 for the 5L. The overall ceiling effect decreased from 29.6% (3L) to 25.5% (5L). Absolute discriminatory power improved (mean Shannon index 0.84 vs. 1.18). The 3L correlated stronger with EQ VAS and CDAI scores, whereas the 5L with PDAI. The 5L demonstrated a better known-groups validity on the basis of age, perianal fistulas, extraintestinal manifestations and disability. This is the first study to report the impact of CD on quality of life using the EQ-5D-5L questionnaire. The 5L seems to perform better than 3L in terms of feasibility, ceiling effect, discriminatory power and known-groups validity. Understanding the differences in psychometrics between the 3L and 5L is essential as they have substantial implications for financial decision-making about CD treatments.

Identifiants

pubmed: 30225788
doi: 10.1007/s11136-018-2003-4
pii: 10.1007/s11136-018-2003-4
doi:

Types de publication

Journal Article

Langues

eng

Sous-ensembles de citation

IM

Pagination

141-152

Références

Health Econ. 2018 Jan;27(1):7-22
pubmed: 28833869
Qual Life Res. 2016 Nov;25(11):2693-2710
pubmed: 27472992
Med Care. 2007 Mar;45(3):259-63
pubmed: 17304084
Qual Life Res. 2013 Sep;22(7):1717-27
pubmed: 23184421
Qual Life Res. 2014 Oct;23(8):2355-63
pubmed: 24627090
Pharmacoeconomics. 2018 Jun;36(6):645-661
pubmed: 29572719
Clin Gastroenterol Hepatol. 2016 Mar;14(3):348-354.e17
pubmed: 26071941
Pharmacoeconomics. 2017 Dec;35(Suppl 1):11-19
pubmed: 29052162
World J Gastroenterol. 2015 Feb 14;21(6):1728-37
pubmed: 25684937
Pilot Feasibility Stud. 2017 Apr 3;3:17
pubmed: 28373911
Value Health. 2010 Mar-Apr;13(2):188-95
pubmed: 19883407
Lancet. 1986 Feb 8;1(8476):307-10
pubmed: 2868172
Expert Rev Pharmacoecon Outcomes Res. 2016;16(1):119-25
pubmed: 26162458
Arch Dermatol Res. 2017 Jul;309(5):357-370
pubmed: 28528371
Lancet. 2006 Sep 9;368(9539):917-8
pubmed: 16962878
Qual Life Res. 2017 Dec;26(12):3409-3419
pubmed: 28875430
Inflamm Bowel Dis. 2009 May;15(5):742-9
pubmed: 19023861
Ann Oncol. 2012 Sep;23 Suppl 10:x294-301
pubmed: 22987980
Gut. 1987 Apr;28(4):474-81
pubmed: 3583074
Gastroenterology. 2002 Feb;122(2):512-30
pubmed: 11832465
JAMA. 2016 Sep 13;316(10):1093-103
pubmed: 27623463
Eur J Gastroenterol Hepatol. 2002 Nov;14(11):1205-15
pubmed: 12439115
Expert Rev Pharmacoecon Outcomes Res. 2017 Dec;17(6):597-606
pubmed: 28434387
J Clin Gastroenterol. 1995 Jan;20(1):27-32
pubmed: 7884173
Inflamm Bowel Dis. 2010 Jan;16(1):42-51
pubmed: 19475674
Health Policy. 1996 Jul;37(1):53-72
pubmed: 10158943
Qual Life Res. 2013 Sep;22(7):1707-16
pubmed: 23192232
Trials. 2015 Oct 06;16:444
pubmed: 26445224
Qual Life Res. 2011 Dec;20(10):1727-36
pubmed: 21479777
PLoS One. 2017 Oct 3;12(10):e0185500
pubmed: 28973005
J Crohns Colitis. 2014 Feb;8(2):93-106
pubmed: 23746864
Psychol Bull. 1979 Mar;86(2):420-8
pubmed: 18839484
Value Health. 2012 Jul-Aug;15(5):708-15
pubmed: 22867780
Cochrane Database Syst Rev. 2016 Aug 08;(8):CD010642
pubmed: 27501379
Value Health. 2007 May-Jun;10(3):214-20
pubmed: 17532814
Pharmacoeconomics. 2018 Jun;36(6):675-697
pubmed: 29470821
Pharmacoeconomics. 2018 Jun;36(6):699-713
pubmed: 29476363
Expert Rev Pharmacoecon Outcomes Res. 2016 Aug;16(4):441-53
pubmed: 27187028
Gastroenterology. 1979 Oct;77(4 Pt 2):829-42
pubmed: 38175
Qual Life Res. 2015 Jun;24(6):1555-63
pubmed: 25425288
Nat Rev Gastroenterol Hepatol. 2015 Dec;12(12):720-7
pubmed: 26323879
Health Qual Life Outcomes. 2016 Jun 08;14:89
pubmed: 27267761
Inflamm Bowel Dis. 2011 Jan;17(1):118-26
pubmed: 20848538
Curr Med Chem. 2019;26(2):259-269
pubmed: 28393687
World J Gastroenterol. 2017 Sep 14;23(34):6294-6305
pubmed: 28974896
Qual Life Res. 2015 Apr;24(4):829-35
pubmed: 25355653
Qual Life Res. 2008 Apr;17(3):463-73
pubmed: 18320352
Clin Orthop Relat Res. 2015 Nov;473(11):3383-90
pubmed: 25488404
Lancet. 2017 Apr 29;389(10080):1741-1755
pubmed: 27914655
PLoS One. 2015 Dec 16;10(12):e0145087
pubmed: 26675292
Health Policy. 1990 Dec;16(3):199-208
pubmed: 10109801
Value Health. 2018 Jan;21(1):49-56
pubmed: 29304940
Value Health. 2008 Mar-Apr;11(2):275-84
pubmed: 18380640
United European Gastroenterol J. 2018 Mar;6(2):310-321
pubmed: 29511561
Lancet. 2018 Dec 23;390(10114):2769-2778
pubmed: 29050646
Qual Life Res. 2015 Jul;24(7):1767-74
pubmed: 25540029
Pharmacoeconomics. 2018 Jun;36(6):637-640
pubmed: 29480350
Qual Life Res. 2012 Aug;21(6):1065-73
pubmed: 21947656
Med Care. 1997 Nov;35(11):1095-108
pubmed: 9366889
J Crohns Colitis. 2016 Mar;10(3):239-54
pubmed: 26614685

Auteurs

Fanni Rencz (F)

Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, 1093, Hungary. fanni.rencz@uni-corvinus.hu.
Premium Postdoctoral Research Program, Hungarian Academy of Sciences, Nádor u. 7, Budapest, 1051, Hungary. fanni.rencz@uni-corvinus.hu.

Peter L Lakatos (PL)

1st Department of Medicine, Semmelweis University, Korányi Sándor u. 2/a, Budapest, 1083, Hungary.
Division of Gastroenterology, McGill University, MUHC, Montreal General Hospital, 1650 Ave. Cedar, D16.173.1, Montreal, QC, H3G 1A4, Canada.

László Gulácsi (L)

Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, 1093, Hungary.

Valentin Brodszky (V)

Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, 1093, Hungary.

Zsuzsanna Kürti (Z)

1st Department of Medicine, Semmelweis University, Korányi Sándor u. 2/a, Budapest, 1083, Hungary.

Szilvia Lovas (S)

Division of Gastroenterology, Department of Internal Medicine, University of Debrecen, Nagyerdei krt. 98., Debrecen, 4032, Hungary.

János Banai (J)

Medical Centre, Hungarian Defence Forces, Podmaniczky u. 109-111, Budapest, 1062, Hungary.

László Herszényi (L)

Medical Centre, Hungarian Defence Forces, Podmaniczky u. 109-111, Budapest, 1062, Hungary.

Tamás Cserni (T)

Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, 1093, Hungary.
Faculty of Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, 1093, Hungary.

Tamás Molnár (T)

1st Department of Internal Medicine, University of Szeged, Korányi fasor 8-10, Szeged, 6720, Hungary.

Márta Péntek (M)

Department of Health Economics, Corvinus University of Budapest, Fővám tér 8, Budapest, 1093, Hungary.

Károly Palatka (K)

Division of Gastroenterology, Department of Internal Medicine, University of Debrecen, Nagyerdei krt. 98., Debrecen, 4032, Hungary.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH